Literature DB >> 2449110

NIH conference. Hepatocellular carcinoma.

A M Di Bisceglie, V K Rustgi, J H Hoofnagle, G M Dusheiko, M T Lotze.   

Abstract

Hepatocellular carcinoma is the most frequent cancer worldwide, responsible for approximately 1,000,000 deaths annually, most of them in the Far East and in sub-Saharan Africa. It usually presents at an advanced stage and has a poor prognosis. There is evidence of an etiologic role for hepatitis B virus infection in the etiology of hepatocellular carcinoma. Carriers of the virus are 94 times more at risk for hepatocellular carcinoma than noncarriers. In many cases hepatitis B virus DNA is integrated within the cellular genome of the tumor. Programs have been established to detect hepatocellular carcinoma at an early stage; persons at high risk are regularly screened by measurement of serum alpha-fetoprotein levels and ultrasound examination of the liver. Surgical resection offers the only hope of cure at present, as chemotherapy, radiotherapy, and immunotherapy have not shown promise. Ideally, surgery should be done on small asymptomatic tumors.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2449110     DOI: 10.7326/0003-4819-108-3-390

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  91 in total

1.  Microinjection technique used to study functional interaction between p53 and hepatitis B virus X gene in apoptosis.

Authors:  X W Wang
Journal:  Mol Biotechnol       Date:  2001-06       Impact factor: 2.695

Review 2.  Treatment strategies for hepatocellular carcinoma in cirrhosis.

Authors:  W Scott Helton; Adrian Di Bisceglie; Ravi Chari; Myron Schwartz; Jordi Bruix
Journal:  J Gastrointest Surg       Date:  2003 Mar-Apr       Impact factor: 3.452

3.  Hepatocellular carcinoma.

Authors:  T Ezaki
Journal:  BMJ       Date:  1992-01-25

Review 4.  Therapeutic management algorithm in cirrhotic and noncirrhotic patients in primary or secondary liver masses.

Authors:  Eldo Ermenegildo Frezza
Journal:  Dig Dis Sci       Date:  2004-05       Impact factor: 3.199

5.  Genetic variation in the NBS1 gene is associated with hepatic cancer risk in a Chinese population.

Authors:  Ming-De Huang; Xiao-Fei Chen; Gang Xu; Qing-Quan Wu; Jian-Huai Zhang; Guo-Feng Chen; Yong Cai; Fu-Zhen Qi
Journal:  DNA Cell Biol       Date:  2011-11-09       Impact factor: 3.311

6.  Intraarterial hepatic chemotherapy with fluorouracil, fluorodeoxyuridine, mitomycin C, cisplatin or methotrexate as single-agent anticancer drugs for a transplanted experimental liver tumor in rats.

Authors:  S Kurth; D Bulian; B Kreft; T Riemenschneider
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

Review 7.  Biological treatment for liver tumor and new potential biomarkers.

Authors:  Maurizio Chiriva-Internati; Fabio Grizzi; Mitchell S Wachtel; Marjorie Jenkins; Raffaele Ferrari; Everardo Cobos; Eldo E Frezza
Journal:  Dig Dis Sci       Date:  2007-08-22       Impact factor: 3.199

8.  In vivo assessment of angioarchitecture and microcirculation in experimental liver cancer: a new model in rats.

Authors:  S M Maksan; H Paulo; E Ryschich; C Kuntz; M M Gebhard; E Klar; J Schmidt
Journal:  Dig Dis Sci       Date:  2003-02       Impact factor: 3.199

9.  Combined resection and radiofrequency ablation for advanced hepatic malignancies: results in 172 patients.

Authors:  Timothy M Pawlik; Francesco Izzo; Deborah S Cohen; Jeffery S Morris; Steven A Curley
Journal:  Ann Surg Oncol       Date:  2003-11       Impact factor: 5.344

10.  Extensive oxidative DNA damage in hepatocytes of transgenic mice with chronic active hepatitis destined to develop hepatocellular carcinoma.

Authors:  T M Hagen; S Huang; J Curnutte; P Fowler; V Martinez; C M Wehr; B N Ames; F V Chisari
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-20       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.